The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 13 of the 37 sources its claims cite were checked for support.
Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis
Open accessAbstract
Background: Persistent symptoms in hypothyroid patients despite normalized TSH levels suggest the need for alternative treatments. This study aims to evaluate the effectiveness of combined T4 and T3 therapy or desiccated thyroid (DTE) compared to T4 monotherapy, with a focus on thyroid profile, lipid profile, and quality of life metrics. Methods: We conducted a systematic review in Embase, Medline/PubMed, and Web of Science up to 11/23/2023. We used the following keywords: “Armour Thyroid,” OR “Thyroid extract,” OR “Natural desiccated thyroid,” OR “Nature-Throid,” “desiccated thyroid,” OR “np thyroid,” OR “Synthroid,” OR “levothyroxine,” OR “Liothyronine,” “Cytomel,” OR “Thyroid USP,” OR “Unithroid.” AND “hypothyroidism. “ We only included RCTs and excluded non-RCT, case–control studies, and non-English articles. Results: From 6,394 identified records, 16 studies qualified after screening and eligibility checks. We included two studies on desiccated thyroid and 15 studies on combined therapy. In this meta-analysis, combination therapy with T4 + T3 revealed significantly lower Free T4 levels (mean difference (MD): -0.34; 95% CI: -0.47, -0.20), Total T4 levels (mean difference: -2.20; 95% CI: -3.03, -1.37), and GHQ-28 scores (MD: -2.89; 95% CI: -3.16, -2.63), compared to T4 monotherapy. Total T3 levels were significantly higher in combined therapy (MD: 29.82; 95% CI: 22.40, 37.25). The analyses demonstrated moderate to high heterogeneity. There was no significant difference in Heart Rate, SHBG, TSH, Lipid profile, TSQ-36, and BDI Score. Subjects on DTE had significantly higher serum Total T3 levels (MD: 50.90; 95% CI: 42.39, 59.42) and significantly lower serum Total T4 (MD: -3.11; 95% CI: -3.64, -2.58) and Free T4 levels (MD: -0.50; 95% CI: -0.57, -0.43) compared to T4 monotherapy. Moreover, DTE treatment showed modestly higher TSH levels (MD: 0.49; 95% CI: 0.17, 0.80). The analyses indicated low heterogeneity. There was no significant difference in Heart Rate, SHBG, Lipid profile, TSQ-36, GHQ-28, and BDI Score. Conclusions: Our study revealed that combined therapy and DTE lead to higher T3 and lower T4 levels, compared to T4 monotherapy in hypothyroidism. However, no significant effects on heart rate, lipid profile, or quality of life were noted. Given the heterogeneity of results, personalized treatment approaches are recommended.
Overview
CoChat Summary
TL;DR
This systematic review and meta-analysis of RCTs found that combined T4+T3 therapy and desiccated thyroid extract (DTE) produce higher T3 and lower T4 levels than T4 monotherapy in hypothyroidism, without consistent significant effects on heart rate, lipids, or most quality-of-life measures. The authors conclude that biochemical differences do not clearly translate into broad clinical benefits and recommend personalized treatment approaches.
Key findings
- Combined T4+T3 vs T4 monotherapy: significantly lower Free T4 (MD −0.34; 95% CI −0.47 to −0.20), Total T4 (MD −2.20; 95% CI −3.03 to −1.37), and higher Total T3 (MD 29.82; 95% CI 22.40 to 37.25). TSH did not differ significantly (MD 0.20; 95% CI −0.63 to 1.04; P=0.63).
- Combined T4+T3 showed no significant differences in heart rate, SHBG, LDL, total cholesterol, HDL, triglycerides, TSQ-36, or BDI. The abstract reports significantly lower GHQ-28 scores (MD −2.89; 95% CI −3.16 to −2.63), but the Results text and Table 1 report GHQ-28 MD 1.71 (95% CI −1.82 to 5.23; P=0.34) and describe no significant impact; the Discussion nonetheless states a notable mental-health improvement.
- DTE vs T4 monotherapy: significantly higher Total T3 (MD 50.90; 95% CI 42.39 to 59.42), lower Total T4 (MD −3.11; 95% CI −3.64 to −2.58), lower Free T4 (MD −0.50; 95% CI −0.57 to −0.43), and modestly higher TSH (MD 0.49; 95% CI 0.17 to 0.80).
- DTE showed no significant differences in heart rate, SHBG, lipid profile, TSQ-36, GHQ-28, BDI, or cognitive/mental-health scores; heterogeneity was generally low for DTE analyses.
Methods
- Systematic review and meta-analysis registered in PROSPERO (CRD42023486957), searching Embase, Medline/PubMed, and Web of Science up to 23 November 2023.
- Included randomized controlled trials of adults ≥18 years with primary hypothyroidism receiving combined T4/T3 or DTE versus levothyroxine; excluded non-RCTs, case–control studies, pregnancy/pediatric patients, and non-English articles.
- From 6,394 records, 16 studies qualified; the abstract describes two DTE studies and 15 combined-therapy studies. Mean differences with 95% CIs were pooled in RevMan, with heterogeneity assessed by I².
Limitations
- The paper states high heterogeneity in some outcomes, potential language bias from excluding non-English studies, and concerns about publication bias; risk-of-bias assessment found high risk in blinding and incomplete outcome data domains.
- The text makes evident that DTE conclusions rest on only two RCTs, and the GHQ-28 result is reported inconsistently across the abstract, Results, Table 1, and Discussion.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
10 Valid · 0 Not valid · 8 Not checked · 97 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“synthetic levothyroxine (LT4) as standard treatment, which effectively normalizes thyroid-stimulating hormone (TSH) levels in most patients”
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Introduction
What the sources say
- Supportedcites [4] Hughes K, Eastman C. Thyroid disease: Long-term management of hyperthyroidism and hypothyroidism. Aust J Gen Pract. 2021;50:36–42. https://doi.org/10.31128/AJGP-09-20-5653. source
The Goals of hypothyroidism treatment section says oral LT4 readily restores a euthyroid state in almost all patients and that TSH should generally be targeted within the reference range. This supports the claim that LT4 normalizes TSH in most patients. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“approximately 5–10% of patients report persistent symptoms such as fatigue and mood disturbances, even when TSH levels are normalized [5, 6].”
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Introduction
What the sources say
- Partly supportedcites [5] Bjerkreim BA, Hammerstad SS, Gulseth HL, Berg TJ, Lee-Odegard S, Eriksen EF. Thyroid signaling biomarkers in female symptomatic hypothyroid patients on liothyronine versus levothyroxine monotherapy: a randomized crossover trial. J Thyroid Res. 2022;2022:6423023. https://doi.org/10.1155/2022/6423023. sourceExperimental — accuracy not yet measured
The Introduction states that 5–10% of hypothyroid patients have residual symptoms despite levothyroxine treatment assessed by normal TSH, and it lists fatigue among the typical symptoms. It lists memory loss and cold intolerance, but does not identify mood disturbances as a typical symptom in that passage. No page number is available in our copy. (LLM, conf=0.86)
- Could not verifycites [6] Salam S, Nso N, Kondaveeti R, Ching THS, Nassar M, Sachmechi I. Efficacy of I-131 treatment dosage for hyperthyroidism with current institution formula. J Endocrinol Metabol. 2023;13:49–56. https://doi.org/10.14740/jem874. sourceExperimental — accuracy not yet measured
The Primary and secondary endpoints section discusses symptoms only as a reason to suspect hypothyroidism when laboratory results are inconclusive or unconfirmed. The post-treatment results report thyroid-status and TSH outcomes, but our copy does not address persistent fatigue or mood disturbances despite normalized TSH, or the claimed 5–10% frequency (searched for those symptoms and the percentage). Page numbers were not available in our copy. (LLM, conf=0.76)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These persistent symptoms suggest that TSH levels may not fully reflect the thyroid hormone status at the tissue level”
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Introduction
What the sources say
- Partly supportedcites [7] Hoang TD, Brooks DI, Bianco A, McAninch EA, Fonseca TL, Mai VQ, Shakir MKM. Desiccated thyroid extract versus synthetic LT4/T3 combination versus LT4 monotherapy in the treatment of primary hypothyroidism with special attention to the Thr92AlaD2 polymorphism. with special attention to the gene polymorphism. J Endocr Soc. 2021;5:A827–8. https://doi.org/10.1210/jendso/bvab048.1687. sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says some patients continue to feel unwell despite LT4 dosing considered adequate by serum TSH levels. That supports the concern that TSH does not capture every aspect of their condition, but the paper does not assess thyroid hormone status at the tissue level or establish it as the reason for their symptoms. (LLM, conf=0.82)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“There was no significant difference in Heart Rate, SHBG, TSH, Lipid profile, TSQ-36, and BDI Score.”
- Also stated in: § Effect of T4 + T3 on thyroid hormone levels · plain
“The analysis of TSH levels in 794 participants across ten studies [9, 12–20], showed no significant difference with a mean change of 0.20 (95% CI: -0.63 to 1.04), confirmed by statistical tests indicating non-significance (P = 0.63)”
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Abstract > Results
What the sources say
- Partly supportedcites [9] Shakir MKM, Brooks DI, McAninch EA, Fonseca TL, Mai VQ, Bianco AC, Hoang TD. Comparative effectiveness of levothyroxine, desiccated thyroid extract, and levothyroxine+liothyronine in hypothyroidism. J Clin Endocrinol Metab. 2021;106:e4400–13. https://doi.org/10.1210/clinem/dgab478. sourceExperimental — accuracy not yet measured
The Secondary Analyses passage says serum TSH varied minimally across the three treatment arms, supporting the reported lack of a meaningful difference between LT4+LT3 and LT4 alone. It does not report the attributed mean difference of 0.20 or 95% CI of −0.63 to 1.04. No page number is available in our copy. (LLM, conf=0.85)
- Not checked — no full text of the sourcecites [12] Clyde PW, Harari AE, Getka EJ, Shakir KM. Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA. 2003;290:2952–8. https://doi.org/10.1001/jama.290.22.2952. source
- Not checked — no full text of the sourcecites [13] Escobar-Morreale HF, Botella-Carretero JI, Gomez-Bueno M, Galan JM, Barrios V, Sancho J. Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med. 2005;142:412–24. https://doi.org/10.7326/0003-4819-142-6-200503150-00007. source
- Not checked — no full text of the sourcecites [14] Fadeyev VV, Morgunova TB, Sytch JP, Melnichenko GA. TSH and thyroid hormones concentrations in patients with hypothyroidism receiving replacement therapy with L-thyroxine alone or in combination with L-triiodothyronine. Hormones (Athens). 2005;4:101–7.
- Not checked — no full text of the sourcecites [15] Fadeyev VV, Morgunova TB, Melnichenko GA, Dedov II. Combined therapy with L-thyroxine and L-triiodothyronine compared to L-thyroxine alone in the treatment of primary hypothyroidism. Hormones (Athens). 2010;9:245–52. https://doi.org/10.14310/horm.2002.1274. source
- Not checked — no full text of the sourcecites [16] Nygaard B, Jensen EW, Kvetny J, Jarlov A, Faber J. Effect of combination therapy with thyroxine (T4) and 3,5,3’-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study. Eur J Endocrinol. 2009;161:895–902. https://doi.org/10.1530/EJE-09-0542. source
- Partly supportedcites [17] Rodriguez T, Lavis VR, Meininger JC, Kapadia AS, Stafford LF. Substitution of liothyronine at a 1:5 ratio for a portion of levothyroxine: effect on fatigue, symptoms of depression, and working memory versus treatment with levothyroxine alone. Endocr Pract. 2005;11:223–33. https://doi.org/10.4158/EP.11.4.223. sourceExperimental — accuracy not yet measured
The Results state that mean TSH did not differ significantly between substitution therapy and T4 alone (p = 0.16). However, Table 4 reports an estimated difference of −2.7 μU/ml for standard treatment minus substitution treatment, not the claimed MD of 0.20, and does not report the claimed 95% CI. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [18] Sawka AM, Gerstein HC, Marriott MJ, MacQueen GM, Joffe RT. Does a combination regimen of thyroxine (T4) and 3,5,3’-triiodothyronine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind, randomized, controlled trial. J Clin Endocrinol Metab. 2003;88:4551–5. https://doi.org/10.1210/jc.2003-030139. source
- Not checked — no full text of the sourcecites [19] Siegmund W, Spieker K, Weike AI, Giessmann T, Modess C, Dabers T, Kirsch G, Sanger E, Engel G, Hamm AO, Nauck M, Meng W. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14: 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf). 2004;60:750–7. https://doi.org/10.1111/j.1365-2265.2004.02050.x. source
- Not checked — no full text of the sourcecites [20] Walsh JP, Shiels L, Lim EM, Bhagat CI, Ward LC, Stuckey BG, Dhaliwal SS, Chew GT, Bhagat MC, Cussons AJ. Combined thyroxine/liothyronine treatment does not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab. 2003;88:4543–50. https://doi.org/10.1210/jc.2003-030249. source
plainn = 794- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Effect of T4 + T3 on thyroid hormone levels · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Despite mixed results in clinical trials, patient preference for combined therapy over T4 alone often arises from subjective improvements in symptoms like fatigue and cognitive function, which are not consistently quantifiable by standard clinical parameters [31].”
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Discussion
What the sources say
- Partly supportedcites [31] Millan-Alanis JM, Gonzalez-Gonzalez JG, Flores-Rodriguez A, Singh Ospina N, Maraka S, Moreno-Pena PJ, Brito JP, Gonzalez-Velazquez C, Rodriguez-Gutierrez R. Benefits and harms of levothyroxine/l-triiodothyronine versus levothyroxine monotherapy for adult patients with hypothyroidism: Systematic Review and Meta-Analysis. Thyroid. 2021;31:1613–25. https://doi.org/10.1089/thy.2021.0270. sourceExperimental — accuracy not yet measured
The Discussion and Results report that patients preferred combined therapy more often than T4 monotherapy (43% versus 23%). They do not establish that this preference arose from perceived improvements in fatigue or cognitive function: the Results found no difference in questionnaire-measured fatigue and lacked data on cognitive outcomes. The claim about improvements not being consistently quantifiable by standard clinical parameters is therefore not established by this review. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
66 more claims
Create a free account to see all 115 claims and every source verdict.
- Probably not a substantial claim. 27
- It may state two separate claims as one. 18
- The quote only partly states this claim. 5
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Results > Effect of T4 + T3 on psychological and quality-of-life measures
“with a highly significant effect and no heterogeneity, pointing to a reliable benefit in mental health”
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Results > Effect of T4 + T3 on thyroid hormone levels
“| GHQ-28 | 2 | 140 | 140 | 4.64 | 2.57 | 1 (P = 0.11) | 61% | 0.95 | 0.34 | 1.71 | [-1.82, 5.23] |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Abstract > Results
“GHQ-28 scores (MD: -2.89; 95% CI: -3.16, -2.63)”
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Results > Effect of T4 + T3 on thyroid hormone levels
“| GHQ-28 | 2 | 140 | 140 | 4.64 | 2.57 | 1 (P = 0.11) | 61% | 0.95 | 0.34 | 1.71 | [-1.82, 5.23] |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Results > Effect of T4 + T3 on psychological and quality-of-life measures
“These findings suggest that while combined T4 + T3 therapy significantly improves mental health, it does not have a marked impact on overall quality of life or depressive symptoms compared to T4 monotherapy (Table 1).”
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Results > Effect of T4 + T3 on thyroid hormone levels
“| GHQ-28 | 2 | 140 | 140 | 4.64 | 2.57 | 1 (P = 0.11) | 61% | 0.95 | 0.34 | 1.71 | [-1.82, 5.23] |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Results > Effect of T4 + T3 on lipid profile
“the analysis of total cholesterol levels in 832 participants from nine studies showed no significant differences between the treatment groups”
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Results > Effect of T4 + T3 on thyroid hormone levels
“| Total cholesterol | 10 | 414 | 418 | 90.48 | 26.88 | 8 (P = 0.0007) | 70% | 1.29 | 0.20 | -5.47 | [-13.80, 2.85] |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Results > Effect of DTE on lipid profile
“Our meta-analysis examined the impact of DTE compared to T4 monotherapy on cholesterol and triglyceride levels across two studies involving 290 participants each.”
§ Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis > Results > Effect of DTE on thyroid hormone levels
“| Total cholesterol | 2 | 145 | 145 | 0.00 | 0.44 | 1 (P = 0.51) | 0% | 0.50 | 0.62 | -2.19 | [-10.76, 6.39] |”
Citations
Cites
Assessing risk of bias in a randomized trial
Higgins, J. P., Savović, J., Page, M. J., Elbers, R. G., & Sterne, J. A. (2019) · Cochrane Handbook for Systematic Reviews of Interventions · doi:10.1002/9781119536604.ch8 · Cited by 1,765 · cited 1×
“We utilized the updated Cochrane risk-of-bias tool for randomized trials (RoB 2) [11] to assess the potential for bias in the included clinical trials.”
MethodBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 1×
“In contrast, the examination of total T4 levels from four studies [9, 17, 21, 22], with 336 participants revealed that subjects on combined therapy had significantly lower levels (mean difference: -2.20, 95% CI: -3.03 to -1.37), with results proving statistically significant ( P 0.00001) (Fig.”
ResultInfluentialTreatment with thyroid hormone
Biondi, B., & Wartofsky, L. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1083 · Cited by 259 · cited 1×
“The variable impacts on metabolic parameters and quality of life, as noted in prior studies on T4 + T3 therapy, may be attributed to the subjective nature of quality-of-life assessments and differing metrics utilized across studies [24].”
Walsh, J. P., Shiels, L., Lim, E. M., Bhagat, C. I., Ward, L. C., Stuckey, B. G. A., Dhaliwal, S. S., Chew, G. T., Bhagat, M. C., & Cussons, A. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030249 · Cited by 210 · cited 2×
“The analysis of TSH levels in 794 participants across ten studies [9, 12–20], showed no significant difference with a mean change of 0.20 (95% CI: -0.63 to 1.04), confirmed by statistical tests indicating non-significance ( P = 0.63) (Fig.”
ResultInfluentialClyde, P. W., Harari, A. E., Getka, E. J., & Shakir, K. M. M. (2003) · JAMA · doi:10.1001/jama.290.22.2952 · Cited by 195 · cited 2×
“The analysis of TSH levels in 794 participants across ten studies [9, 12–20], showed no significant difference with a mean change of 0.20 (95% CI: -0.63 to 1.04), confirmed by statistical tests indicating non-significance ( P = 0.63) (Fig.”
ResultInfluentialEscobar-Morreale, H. F., Botella-Carretero, J. I., Gómez-Bueno, M., Galán, J. M., Barrios, V., & Sancho, J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00007 · Cited by 182
Sawka, A. M., Gerstein, H. C., Marriott, M. J., MacQueen, G. M., & Joffe, R. T. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030139 · Cited by 175 · cited 1×
“Most of the included studies are insignificant [9, 12–18] except for two studies, one showed a lower TSH, and the other showed a higher TSH [19, 20].”
ResultTreatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine
Escobar-Morreale, H. F., Botella-Carretero, J. I., del Rey, F. E., & de Escobar, G. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0184 · Cited by 160
Nygaard, B., Jensen, E. W., Kvetny, J., Jarløv, A., & Faber, J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0542 · Cited by 153
Siegmund, W., Spieker, K., Weike, A. I., Giessmann, T., Modess, C., Dabers, T., Kirsch, G., Sänger, E., Engel, G., Hamm, A. O., et al. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02050.x · Cited by 152 · cited 1×
“Most of the included studies are insignificant [9, 12–18] except for two studies, one showed a lower TSH, and the other showed a higher TSH [19, 20].”
Result
Cited by
Vargas‐Uricoechea, H., & Wartofsky, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179218 · Cited by 14
Hedberg, F., Lindh, J. D., Mannheimer, B., Planck, T., Skov, J., Lehtihet, M., Falhammar, H., & Calissendorff, J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf337 · Cited by 2
Hoang, T. D., Patel, A. A., Spiro, A. J., Watson, N. L., & Shakir, M. K. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.007 · Cited by 2
Wu, J., Huang, J., Yan, Z., Yuan, A., Song, Y., & Huang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1607927 · Cited by 2
“A combination therapy with T3-containing medications such as liothyronine or desiccated thyroid extract should be considered (20, 21).”
Hedberg, F., Lindh, J. D., Mannheimer, B., Planck, T., Skov, J., Falhammar, H., & Calissendorff, J. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag107 · Cited by 1
“Several systematic reviews and meta-analyses of clinical trials have failed to demonstrate an advantage with LT4 + LT3 combination therapy [7-9].”
Metadata
- Authors
- Nassar, M., Hassan, A., Ramadan, S., Desouki, M. T., Hassan, M. A., & Chaudhuri, A.
- Affiliations
- Beni-Suef University (EG)
- Suez University (EG)
- Ain Shams University (EG)
- Alexandria University (EG)
- University at Buffalo, State University of New York (US)
- Corresponding author
- Hassan, Ahmed
- Venue
- BMC Endocrine Disorders
- Published
- 2024-06-14
- Volume
- 24
- Issue
- 1
- Pages
- 90-90
- ISSN
- 1472-6823 (ISSN-L)
- PMC
- PMC11177353
- OpenAlex
- W4399690792
- Cited by
- 12
- References
- 32
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 1
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- BMC Endocrine Disorders (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Keywords
- hypothyroidism, desiccated thyroid extract, levothyroxine, liothyronine, free thyroxine, total T3, thyroid hormone levels, quality of life, lipid profile, thyroid-stimulating hormone, symptom scores, treatment effectiveness comparison
- MeSH terms
- Drug Therapy, Combination, Humans, Hypothyroidism, Quality of Life, Thyroid Gland, Thyroxine, Triiodothyronine, Treatment Outcome, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12902-024-01612-6
- The paper
- Nassar, M., Hassan, A., Ramadan, S., Desouki, M. T., Hassan, M. A., & Chaudhuri, A. (2024). Evaluating the effectiveness of combined T4 and T3 therapy or desiccated thyroid versus T4 monotherapy in hypothyroidism: a systematic review and meta-analysis. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-024-01612-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.